SUBCUTANEOUS INFLIXIMAB IN REFRACTORY CROHN’S DISEASE PATIENTS AFTER THE MULTIPLE TREATMENT FAILURES – SHORT TREATMENT OUTCOMES

Subcutaneous administration of infliximab shows an increased benefit in terms of pharmacokinetics and pharmacodynamics effects compared to the intravenous infliximab.